After the founding of New China, it was directly under the leadership of the Ministry of Health. Now it is an important member of China National Pharmaceutical Group Co., Ltd., a fortune 500 enterprise in the world. It is a comprehensive biopharmaceutical enterprise with a long history, complete products and large scale in China, integrating scientific research, production, sales and postgraduate training. There are 12 secondary subsidiaries, 76 subsidiaries below the secondary level, and employees 1255 1 person.
First, the biological development and scientific research strength of China:
China has a rich biological product line, covering six biological products: vaccines for human use, blood products, medical beauty, animal health care, antibody drugs and medical diagnosis. The annual output of human vaccines is 50 kinds, with an annual output of more than 700 million doses, ranking sixth in the world, providing more than 80% vaccines for the national immunization program.
China has a strong biotechnology innovation strength, with more than 10,000 people in R&D team and more than 10,000 people in quality management team, including academician of China Academy of Engineering, chief scientist of National "863" Vaccine Project, and member of National Pharmacopoeia Committee.
Two. Brief introduction of sinopharm group
China Pharmaceutical Group Co., Ltd., namely China Pharmaceutical Group, is the largest pharmaceutical and health industry group with the most complete industrial chain and the strongest comprehensive strength in China directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. It focuses on distribution, retail, research and development and production of health-related products, such as preventive treatment and diagnostic care. It has more than 65,438+0,500 subsidiaries, and six listed companies, including Sinopharm Holdings, Sinopharm Shares, Sinopharm Consistent, Tiantan Bio, Hyundai Pharmaceutical and China Traditional Chinese Medicine.
China Pharmaceutical Group Co., Ltd. is making every effort to promote the all-round development of five platforms of the Group-modern logistics and distribution integrated operation platform, Industry-University-Research integrated scientific and technological innovation platform, national drug retail chain network, national narcotic drug distribution network, national biological product marketing and cold chain distribution network, national medical device consumables product distribution network, scientific instruments and medical devices, medical research and engineering design, international operation of medicine and overseas industries, medical exhibition and media, and medical health industry, thus forming an innovative type with core competitiveness of medical health industry. Pharmaceutical Group has a pharmaceutical distribution network covering 365,438+0 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers that meet international standards. It is the largest biological R&D and production enterprise in China, and undertakes more than 80% of the production tasks of vaccines under the national immunization program. The group has established production bases and medicinal materials bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infective drugs, anti-tumor drugs, cardiovascular and cerebrovascular drugs and respiratory drugs, and has the strongest applied drug research institutions and engineering design institutes in China. 20 10 China pharmaceutical group co., ltd was awarded as a national innovative enterprise.
20 1 September1,20 19 China top 500 service enterprises ranked 22nd [2]; In April 2020, it was selected into the list of "Science and Technology Reform Demonstration Enterprises" of the State Council State-owned Assets Supervision and Administration Commission; In 2020, the heads of central enterprises will assess the operating performance of A-level enterprises; 202 1 year, ranking among the top 500 in the world 109.